Authored by James Sheppard
The French diagnostic company BioMerieux has completed the purchase of US diagnostic company BioFire Diagnostics for $450m plus BioFire’s net financial debt. The deal is aimed at consolidating BioMerieux’s position as a major player in the infectious disease diagnostics market.
BioFire specialise in producing products which can detect viral and bacterial infections in a single test. BioFire currently manufacturers a number of diagnostic products including its High Multiplex PCR Instrument called FilmArray System. The FilmArray system is approved by the FDA for the detection of 17 respiratory diseases, 3 bacterial pathogens and 100 sepsis causing pathogens. In a statement, BioMerieux stated that FilmArray should be able to detect more than 70 agents responsible for respiratory, GI and blood infections within the next three years. “FilmArray is the only system that makes it possible to detect disease-causing viruses and bacteria using a single reagent,” said Jean-Luc Belingard, chairman and CEO
BioMerieux wants to widen its market share by lowering the manufacturing costs of BioFire’s array panels and using its worldwide distribution network. In-vitro diagnostics for infectious diseases is at the core of BioMerieux’s sales and currently the company makes about 85% of its revenues in this segment of the market. The BioFire acquisition will further bolster BioMerieux’s dominance in the market.